Gossamer Bio
Corporate brand
UnclaimedGossamer Bio is a clinical-stage biopharmaceutical company developing the investigational drug seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Last updated September 16, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development of its investigational drug product, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib is described as an inhaled PDGFRα/β, CSF1R, and c-KIT inhibitor designed to be delivered via dry powder inhaler. The company states that its goal is to enhance the lives of people living with these rare diseases. Its name is explained as depicting the symbolism behind the gossamer thread, the fragile connection that binds all relationships in life, intended to highlight the importance of its relationships with patients, employees, shareholders, providers and partners. The company lists a USA office in San Diego, California, and an Ireland office in Dublin.
History
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development of its investigational drug product, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Faheem Hasnain is described as Co-Founder, Chairman and Chief Executive Officer of Gossamer Bio. The company's name is explained as depicting the symbolism behind the gossamer thread, the fragile connection that binds all relationships in life, intended to highlight the importance of its relationships with patients, employees, shareholders, providers and partners. The company lists a USA office at 3115 Merryfield Row, Suite 120, San Diego, CA 92121, and an Ireland office at 77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands, Dublin 2, D02 VK60.
Products and positioning
Clinical-stage biopharmaceutical company focused on rare pulmonary diseases
Seralutinib
An inhaled PDGFRα/β, CSF1R, and c-KIT inhibitor designed to be delivered via dry powder inhaler for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Recent events
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/gossamer-bio-united-states · Editorial policy · How profiles are compiled